We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Cerebrolysinis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Cerebrolysin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2011–2023 with a typical study size of 597 participants.
Based on 10 studies · 7 meta-analyses · 3 RCTs · 11,816 total participants
Confidence
HighBy outcome
Cerebrolysin has an evidence score of 4/10 — emerging evidence based on 11 indexed studies, including 8 meta-analyses. An injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous. Representative study: PMID 32662068.
The commonly studied dose of Cerebrolysin is Trial regimens vary widely (e.g. 30 mL/day IV for 10-21 days in stroke/dementia; intramuscular injection at lower doses). No validated optimal dose; this is a prescription drug abroad, not a self-administered supplement.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Casein Hydrolysate
Mostly mechanism / observationalA milk-derived bioactive peptide — a tryptic hydrolysate of bovine αs1-casein standardized to the decapeptide α-casozepine (Lactium) — marketed for stress, anxiety, and sleep. Honest appraisal: the mechanism is real and food-derived (α-casozepine binds the benzodiazepine site of the GABA-A receptor in vitro), and a handful of small human RCTs show modest reductions in stress symptoms and cortisol plus some sleep-diary improvements. But several trials are industry-linked, two well-designed sleep RCTs were null on their primary endpoint, and effects are small. Well-tolerated; this is an ordinary dietary supplement, not a drug.
Last reviewed June 2026 · evidence from 10 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Cerebrolysin
An injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous.
Despite many meta-analyses, the highest-quality Cochrane reviews find no stroke benefit (with a possible harm signal) and only very-low-quality dementia evidence, while positive trials are industry-linked, holding the score emerging.
Cerebrolysin is a peptidergic drug produced by the controlled enzymatic breakdown of purified pig (porcine) brain proteins, yielding a mixture of low-molecular-weight neuropeptides and free amino acids.
It is given by intramuscular injection or, at higher doses, intravenous infusion, and is promoted as a 'neurotrophic' / 'neuroprotective' agent — the idea being that its peptides mimic endogenous neurotrophic factors (BDNF/GDNF-like activity) to support neuronal survival and neuroplasticity.
It has been approved and is heavily used for decades in Russia, China, and a number of European, post-Soviet and Asian countries for acute ischaemic stroke, vascular and Alzheimer's dementia, and traumatic brain injury.
It is NOT approved by the US FDA and is not a dietary supplement; it is a biological injectable drug, and any non-prescription/grey-market sourcing carries real sterility and identity risks for a pig-tissue-derived product.
The honest evidence picture is mixed-to-disappointing once the highest-quality syntheses are weighed.
The 2020 Cochrane review of acute ischaemic stroke (7 RCTs, 1601 participants) found Cerebrolysin probably makes little or no difference to all-cause death and concluded there was no demonstrated clinical benefit — while flagging moderate-quality evidence of an INCREASE in non-fatal serious adverse events (RR 2.15, 95% CI 1.01-4.55), more pronounced at the higher 30 mL dosing schedule.
The 2019 Cochrane review of vascular dementia (6 RCTs, 597 participants) found a possible cognitive/global-function signal but rated the evidence very-low-quality, noted all the studies had high risk of bias and most were industry-supported, and cautioned that any real effect may be too small to be clinically meaningful.
Against this sit a series of largely industry-linked positive trials and meta-analyses: the CARS / CARS-1+CARS-2 stroke-rehabilitation trials and the CAPTAIN TBI trials report small-to-medium benefits on motor and functional scales; a 2015 meta-analysis suggested benefit in mild-to-moderate Alzheimer's; and TBI meta-analyses report improved GCS/GOS but no mortality benefit.
Even some positive TBI RCTs miss their primary endpoint (a 2023 three-arm rTMS + Cerebrolysin trial showed only non-significant descriptive trends).
The result is a genuinely mixed body of evidence in which the most rigorous, least-conflicted analyses are null-to-negative for the headline indication (acute stroke) and only weak for dementia. Overall evidence is therefore Emerging.
Cerebrolysin is a mixture of porcine-brain-derived neuropeptides and amino acids said to have properties resembling endogenous neurotrophic factors (e.g. BDNF/GDNF), proposed to support neuronal survival and growth. This is the marketed rationale; it is characterised mainly in preclinical work.
Proposed to limit secondary injury cascades (excitotoxicity, neuroinflammation, apoptosis) and to promote neuroplasticity/neurorecovery after ischaemic or traumatic brain injury. Mechanistic claims outrun the human efficacy data, which are mixed.
How Cerebrolysin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Trial regimens vary widely (e.g. 30 mL/day IV for 10-21 days in stroke/dementia; intramuscular injection at lower doses). No validated optimal dose; this is a prescription drug abroad, not a self-administered supplement.
Can be taken without food
| Form | Type |
|---|---|
| 💊Injectable solution (clinician-administered, where approved) | Recommended |
There is no oral form. Outside the countries where it is an approved drug, there is no legitimate consumer product — sourcing an injectable pig-brain peptide preparation on the grey market is unsafe.
Minimum: 10 days
Optimal: 21 days
Cycling: Not required
Note: Given as daily injections/infusions over a multi-day treatment course under medical supervision; no oral or at-home regimen is established.
Dose-response data unavailable. The current published research for Cerebrolysin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
The Cochrane review of acute ischaemic stroke found no benefit on death or function. Some industry-linked rehabilitation trials (CARS) report motor-recovery gains, so the literature is genuinely mixed — but the highest-quality synthesis is null.
Cochrane found moderate-quality evidence of an increase in non-fatal serious adverse events in acute ischaemic stroke, more pronounced at the higher 30 mL dosing schedule.
A possible cognitive/global-function benefit in vascular dementia, but on very-low-quality, high-risk-of-bias, mostly industry-funded evidence — any real effect may be too small to be clinically meaningful.
TBI meta-analyses (CAPTAIN, others) report small-to-medium gains on functional scales and improved GCS/GOS but no effect on mortality; some RCTs miss their primary endpoint.
The highest-quality synthesis (Cochrane) shows no benefit and a possible increase in non-fatal serious adverse events — weigh this against the marketing claims.
Not adequately studied — avoid.
Listed as a labelling caution; use only under specialist supervision.
Do not. It is a pig-brain-derived injectable biological; unverified product carries sterility, identity and contamination risk and is not FDA-approved.
Product labelling cautions against combining with MAO inhibitors and certain antidepressants because of additive/summation effects; use only under medical supervision.
Labelling advises against co-administration in the same infusion with balanced amino-acid solutions; an injectable drug to be handled clinically, not stacked like a supplement.
Tip: Cochrane found a possible increase in non-fatal serious adverse events in acute ischaemic stroke, more pronounced at the higher 30 mL schedule — a reason for caution, not a benign profile.
Tip: Administer by a clinician; rotate sites.
Tip: Often linked to too-rapid infusion; slow administration.
Tip: Stop immediately; seek medical care. Risk is inherent to an animal-tissue-derived injectable.
The best time to take Cerebrolysin is in the morning. It can be taken on an empty stomach. Administered by injection (intramuscular at lower doses, intravenous infusion at higher doses) in daily treatment courses (commonly 10-21 days) under medical supervision in the countries where it is approved.
Cerebrolysin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are non-fatal serious adverse events (acute stroke setting), injection-site reactions, agitation / feeling hot / sweating / dizziness. Use caution if any of these apply to you: Known hypersensitivity to the product (porcine-derived biological); Severe renal impairment (status epilepticus and epilepsy are listed cautions in product labelling); Pregnancy / breastfeeding (not adequately studied).
Oxytocin
Mostly mechanism / observationalA nine-amino-acid hormone with two very different stories. As an IV drug (Pitocin/Syntocinon) it is an established, supervised hospital medicine for inducing/augmenting labor and controlling postpartum bleeding. As a grey-market intranasal 'love/bonding/trust' spray it is largely UNPROVEN — the largest, most rigorous autism RCT (Sikich 2021, NEJM) was negative on its primary outcome, and replication of the famous single-dose social effects has been poor.